1. Home
  2. MYFW vs MGNX Comparison

MYFW vs MGNX Comparison

Compare MYFW & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MYFW

First Western Financial Inc.

HOLD

Current Price

$31.36

Market Cap

312.1M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$4.40

Market Cap

256.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MYFW
MGNX
Founded
2002
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
312.1M
256.8M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
MYFW
MGNX
Price
$31.36
$4.40
Analyst Decision
Hold
Buy
Analyst Count
1
5
Target Price
$27.00
$5.00
AVG Volume (30 Days)
37.9K
469.2K
Earning Date
04-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
54.02
N/A
EPS
1.20
N/A
Revenue
$96,914,000.00
$149,500,000.00
Revenue This Year
$20.48
N/A
Revenue Next Year
$9.70
$3.19
P/E Ratio
$26.18
N/A
Revenue Growth
7.60
N/A
52 Week Low
$21.96
$1.30
52 Week High
$34.36
$5.08

Technical Indicators

Market Signals
Indicator
MYFW
MGNX
Relative Strength Index (RSI) 51.59 52.75
Support Level $30.08 $3.80
Resistance Level $32.59 $4.38
Average True Range (ATR) 0.65 0.18
MACD 0.01 0.02
Stochastic Oscillator 56.95 61.46

Price Performance

Historical Comparison
MYFW
MGNX

About MYFW First Western Financial Inc.

First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: